Last update :
18/04/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Methotrexate sodium  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Abitrexate Republic of South Africa
Antifolan Romania
Artrait Argentina
Bendatrexat Germany
Biometrox Brazil
Ebetrex Switzerland
Ebetrexate Austria
Emthexat Turkey
Emthexate Belgium, Netherlands, Republic of South Africa, Spain
Ledertrexate Belgium, France, Luxembourg, Morocco
Maxtrex Great Britain
Metex Germany, Norway
Methoblastin Republic of South Africa
Methotrexamed Germany
Methotrexate France
Metoject Chile, Denmark, Finland, France, Great Britain, Netherlands, Spain, Sweden, Switzerland
Metotrexato Chile
Trexan Finland
Trexat Germany
Stability of mixtures   Injection   Stability of mixtures : Methotrexate sodium     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 6,25 mg/ml
Injection   Methotrexate sodium   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Protect from light 57
Level of evidence A+
Glass Elliott’s B solution 0,0279 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,442 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0314 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,484 mg/ml
Injection   Hydrocortisone sodium succinate 0,478 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0581 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,477 mg/ml
Injection   Hydrocortisone sodium succinate 0,467 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0542 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,433 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0721 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,479 mg/ml
Injection   Hydrocortisone sodium succinate 0,489 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0649 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,431 mg/ml
23°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0314 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,484 mg/ml
Injection   Hydrocortisone sodium succinate 0,478 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0279 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,442 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0581 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,477 mg/ml
Injection   Hydrocortisone sodium succinate 0,467 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0542 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,433 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0721 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,479 mg/ml
Injection   Hydrocortisone sodium succinate 0,489 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Glass Elliott’s B solution 0,0649 mg/ml
Injection   Methotrexate sodium   
Injection   Cytarabine 0,431 mg/ml
4°C
48 Hour
Not specified 1661
Level of evidence B
Polyvinyl chloride Glucose 5% 0,5 & 6 mg/ml
Injection   Methotrexate sodium   
Injection   Ondansetron hydrochloride 0,03 & 0,3 mg/ml
21°C-23°C
48 Hour
Light 184
Level of evidence C+
Polypropylen Syringe NaCl 0,9% or Glucose 5% 1 mg/ml
Injection   Methotrexate sodium   
Injection   Hydrocortisone sodium succinate 2 mg/ml
Injection   Cytarabine 4,1 mg/ml
25°C
24 Hour
Not specified 1028
Level of evidence A
Polypropylen Syringe Sodium chloride 0,9% 5,3 mg/ml
Injection   Methotrexate sodium   
Injection   Methylprednisolone sodium succinate 0,8 mg/ml
24-26°C
6 Hour
Protect from light 4641
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 3 mg/ml
Injection   Methotrexate sodium   
Injection   Methylprednisolone sodium succinate 0,5 mg/ml
24-26°C
6 Hour
Protect from light 4641
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 3 mg/ml
Injection   Methotrexate sodium   
Injection   Hydrocortisone sodium succinate 2,5 mg/ml
24-26°C
24 Hour
Protect from light 4641
Level of evidence A+
Polypropylen Syringe Sodium chloride 0,9% 6 mg/ml
Injection   Methotrexate sodium   
Injection   Hydrocortisone sodium succinate 4 mg/ml
24-26°C
24 Hour
Protect from light 4641
Level of evidence A+
Polypropylen Syringe Ringer’s lactate solution 1 mg/ml
Injection   Methotrexate sodium   
Injection   Hydrocortisone sodium succinate 2 mg/ml
Injection   Cytarabine 4,1 mg/ml
25°C
24 Hour
Not specified 1028
Level of evidence A
Polypropylen Syringe Elliott’s B solution 1 mg/ml
Injection   Methotrexate sodium   
Injection   Hydrocortisone sodium succinate 2 mg/ml
Injection   Cytarabine 4,1 mg/ml
25°C
24 Hour
Not specified 1028
Level of evidence A
Polypropylen Syringe None 1,54 mg/ml
Injection   Methotrexate sodium   
Injection   Methylprednisolone sodium succinate 0,51 mg/ml
Injection   Cytarabine 3,85 mg/ml
5°C
12 Hour
Protect from light 3275
Level of evidence A
  Mentions Légales